These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 32316260)

  • 21. Tumor Microenvironment-Induced Immunometabolic Reprogramming of Natural Killer Cells.
    Chambers AM; Lupo KB; Matosevic S
    Front Immunol; 2018; 9():2517. PubMed ID: 30467503
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer Immunotherapy Targets Based on Understanding the T Cell-Inflamed Versus Non-T Cell-Inflamed Tumor Microenvironment.
    Gajewski TF; Corrales L; Williams J; Horton B; Sivan A; Spranger S
    Adv Exp Med Biol; 2017; 1036():19-31. PubMed ID: 29275462
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer.
    Hatfield SM; Sitkovsky M
    Curr Opin Pharmacol; 2016 Aug; 29():90-6. PubMed ID: 27429212
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Antitumor Cytotoxic Response: If the Killer Cells Play the Music, the Microenvironmental Hypoxia Plays the Tune.
    Chouaib S
    Crit Rev Immunol; 2020; 40(2):157-166. PubMed ID: 32749093
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The interaction of NK cells and dendritic cells in the tumor environment: how to enforce NK cell & DC action under immunosuppressive conditions?
    Jacobs B; Ullrich E
    Curr Med Chem; 2012; 19(12):1771-9. PubMed ID: 22414086
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors.
    Eckert F; Zwirner K; Boeke S; Thorwarth D; Zips D; Huber SM
    Front Immunol; 2019; 10():407. PubMed ID: 30930892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The Contribution of the Immune System in Bone Metastasis Pathogenesis.
    Xiang L; Gilkes DM
    Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30823602
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metabolism of Dendritic Cells in Tumor Microenvironment: For Immunotherapy.
    Peng X; He Y; Huang J; Tao Y; Liu S
    Front Immunol; 2021; 12():613492. PubMed ID: 33732237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 3: PD-L1, Intracellular Signaling Pathways and Tumor Microenvironment.
    Palicelli A; Croci S; Bisagni A; Zanetti E; De Biase D; Melli B; Sanguedolce F; Ragazzi M; Zanelli M; Chaux A; Cañete-Portillo S; Bonasoni MP; Soriano A; Ascani S; Zizzo M; Castro Ruiz C; De Leo A; Giordano G; Landriscina M; Carrieri G; Cormio L; Berney DM; Gandhi J; Copelli V; Bernardelli G; Santandrea G; Bonacini M
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Type I interferon-mediated tumor immunity and its role in immunotherapy.
    Yu R; Zhu B; Chen D
    Cell Mol Life Sci; 2022 Mar; 79(3):191. PubMed ID: 35292881
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity.
    Janji B; Berchem G; Chouaib S
    Front Immunol; 2018; 9():887. PubMed ID: 29922284
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
    Albini A; Bruno A; Noonan DM; Mortara L
    Front Immunol; 2018; 9():527. PubMed ID: 29675018
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allies or Enemies-The Multifaceted Role of Myeloid Cells in the Tumor Microenvironment.
    Haas L; Obenauf AC
    Front Immunol; 2019; 10():2746. PubMed ID: 31849950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Cell-Derived Exosomes in the Cancer-Immunity Cycle.
    Yan W; Jiang S
    Trends Cancer; 2020 Jun; 6(6):506-517. PubMed ID: 32460004
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hijacked Immune Cells in the Tumor Microenvironment: Molecular Mechanisms of Immunosuppression and Cues to Improve T Cell-Based Immunotherapy of Solid Tumors.
    Balta E; Wabnitz GH; Samstag Y
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanomicelle protects the immune activation effects of Paclitaxel and sensitizes tumors to anti-PD-1 Immunotherapy.
    Yang Q; Shi G; Chen X; Lin Y; Cheng L; Jiang Q; Yan X; Jiang M; Li Y; Zhang H; Wang H; Wang Y; Wang Q; Zhang Y; Liu Y; Su X; Dai L; Tang M; Li J; Zhang L; Qian Z; Yu D; Deng H
    Theranostics; 2020; 10(18):8382-8399. PubMed ID: 32724476
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunogenic and Non-immunogenic Cell Death in the Tumor Microenvironment.
    Pitt JM; Kroemer G; Zitvogel L
    Adv Exp Med Biol; 2017; 1036():65-79. PubMed ID: 29275465
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy.
    Abou Khouzam R; Goutham HV; Zaarour RF; Chamseddine AN; Francis A; Buart S; Terry S; Chouaib S
    Semin Cancer Biol; 2020 Oct; 65():140-154. PubMed ID: 31927131
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.
    Seliger B
    HLA; 2016 Nov; 88(5):213-220. PubMed ID: 27659281
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytokines Orchestrating the Natural Killer-Myeloid Cell Crosstalk in the Tumor Microenvironment: Implications for Natural Killer Cell-Based Cancer Immunotherapy.
    Gaggero S; Witt K; Carlsten M; Mitra S
    Front Immunol; 2020; 11():621225. PubMed ID: 33584718
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.